Saturday, June 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC, under fire for COVID response, announces plans to revamp agency

Centers for Disease Control and Prevention Director Rochelle Walensky announced plans to revamp the agency that has come under blistering criticism for its performance leading the U.S. response to the coronavirus pandemic, saying, “it is time to step back and strategically position CDC to support the future of public health.”

In an agencywide email sent shortly after 1 p.m., Walensky said she has hired a senior federal health official outside of the Atlanta-based agency to conduct a one-month review to “kick off an evaluation of CDC’s structure, systems, and processes.”

“Over the past year, I have heard from many of you that you would like to see CDC build on its rich history and modernize for the world around us,” she wrote in the email. “I am grateful for your efforts to lean into the hard work of transforming CDC for the better. I look forward to our collective efforts to position CDC, and the public health community, for greatest success in the future.”

Source: Washington Post

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!